Marco Tagliamento

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 103 publications

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.

Journal: Expert opinion on pharmacotherapy

Published: July 23, 2026

The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective.

The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 10, 2026

First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis.

First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 01, 2026

Targeted therapies in non-small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management.

Targeted therapies in non-small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management.

Journal: Frontiers in pharmacology

Published: January 19, 2026

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Journal: Clinical lung cancer

Published: January 11, 2026

NSCLC in Vulnerable and Special Populations: Toward Personalized Care.

NSCLC in Vulnerable and Special Populations: Toward Personalized Care.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 15, 2025

Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.

Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 13, 2025

The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology.

The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology.

Journal: Cancer treatment reviews

Published: November 22, 2025

Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies.

Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 01, 2025

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 15, 2025

Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer.

Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 08, 2025

Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.

Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.

Journal: ESMO open

Published: March 15, 2025

Showing 1-12 of 103

Last Updated: 09/26/2026